Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Akeso Biopharma Inc (9926 HK)
Watchlist
211
Analysis
Health Care
•
China
Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
PDD Holdings
•
07 Feb 2023 05:36
EM Outperformance to Continue (Vs. EAFE) -- Add on a Pullback; DXY Needs to Hold Below $106
EM vs. EAFE ratio (local currency) shows EM has outperformed relative to EAFE since the $DXY peaked in November 2022. If the DXY remains below...
Vermilion Research
Follow
364 Views
Share
bearish
•
Alphamab Co Ltd
•
06 Feb 2023 08:55
Alphamab Co Ltd Placement (9966.HK) - Has No Potential to Be a Biopharma; Just Remain as a Biotech
We doubt the competitiveness of Alphamab's products. Its credibility has also been affected. It's more suitable for short-term trade than long-term...
Xinyao (Criss) Wang
Follow
329 Views
Share
bullish
•
Thematic (Sector/Industry)
•
29 Jan 2023 09:17
China Healthcare Weekly (Jan.27) - Surgical Robots New Policy, COVID-19 Update, Policy Vacuum Period
New policy released to support development of surgical robot. COVID-19 is no longer an excuse for company's poor performance. It's a good time to...
Xinyao (Criss) Wang
Follow
356 Views
Share
bullish
•
Hutchmed China Ltd
•
25 Jan 2023 08:55
Hutchmed China Ltd (13.HK/HCM.US) - The $1.13B Eye-Catching Deal with Takeda and the New Outlook
HUTCHMED/Takeda $1.13 billion license agreement is very worthy of learning.Together with savolitinib's inclusion in new NRDL,2023 performance...
Xinyao (Criss) Wang
Follow
378 Views
Share
bullish
•
JW Therapeutics
•
23 Jan 2023 09:26
China Healthcare Weekly (Jan.20) - NRDL Negotiation Results, JW Therapeutics, Sirnaomics, Antengene
We analyzed 2022 NRDL negotiation result - There're positive sides.The "safety pad" brought by medical insurance coverage may not be high.We...
Xinyao (Criss) Wang
Follow
435 Views
Share
First
Previous
15
16
17
18
19
20
21
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x